Hims & Hers Health (HIMS) AI Stock Analysis

• Market Cap: $13.07B
• Dividend Yield: N/A
• Average Volume (3M): 27.16M
• Price to Earnings (P/E): 72.4
• Beta (1Y): 2.61
• Revenue Growth: 88.69%
• EPS Growth: 947.74%
• Country: US
• Employees: 1,637
• Sector: Consumer Defensive
• Sector Strength: 42
• Industry: Household & Personal Products
• EPS (TTM): 0.17
• Shares Outstanding: 217,641,950
• 10 Day Avg. Volume: 33,417,998
• 30 Day Avg. Volume: 27,158,634
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.97
• Enterprise Value/Revenue: 6.31
• Enterprise Value/Gross Profit: 8.28
• Enterprise Value/Ebitda: 82.06
• 1Y Price Target: $49.40
• Price Target Upside: -14.56% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 12

• Rating: 69 Neutral
• Price Target: $53.00 ▼(-8.34% Downside)

Hims & Hers Health's overall score is driven by strong financial performance and positive earnings call sentiment, indicating growth potential. However, high leverage, cash flow concerns, and a high P/E ratio suggest caution. The company's strategic expansions and technological advancements are promising, but operational challenges and valuation concerns temper the outlook.

Positive Factors

Revenue Growth

Strong revenue growth indicates robust market demand and successful execution of business strategies, supporting long-term expansion.

International Expansion

International expansion through strategic acquisitions enhances market reach and diversifies revenue streams, strengthening global competitiveness.

Technological Advancements

Investments in AI and technology improve patient care and engagement, positioning the company as a leader in digital health innovation.

Negative Factors

High Leverage

High leverage can increase financial risk, limiting flexibility and potentially impacting long-term financial stability if not managed effectively.

Declining Free Cash Flow

Declining free cash flow growth may hinder the company's ability to invest in growth opportunities and manage debt, affecting long-term liquidity.

Increased Costs

Rising costs, particularly in G&A, can pressure margins and profitability, challenging the company's ability to maintain cost efficiency over time.

Hims & Hers Health Business Overview & Revenue Model

Company Description

Hims & Hers Health (HIMS) is a telehealth company focused on providing accessible healthcare solutions primarily for men and women. Founded in 2017, the company operates in the digital health sector, offering a range of products and services including prescription medications for conditions such as erectile dysfunction, hair loss, and skincare, as well as wellness products like vitamins and supplements. HIMS leverages a direct-to-consumer model, utilizing an online platform that allows customers to consult with licensed healthcare professionals and receive treatment through a convenient digital experience.

How the Company Makes Money

Hims & Hers Health generates revenue through multiple streams, primarily by selling prescription medications and health-related products directly to consumers. The company operates on a subscription-based model for certain products, which provides recurring revenue. Additionally, HIMS earns income from telehealth consultations, where customers pay for access to healthcare providers. Strategic partnerships with pharmacies and healthcare networks also contribute to its revenue, enabling HIMS to efficiently distribute its products. The company's focus on branding and marketing enhances customer acquisition, further driving sales and profitability.

Hims & Hers Health Financial Statement Overview

Summary

Hims & Hers Health shows strong revenue growth and profitability with a healthy gross profit margin. However, high leverage and declining free cash flow growth present potential risks. The company needs to focus on improving cash flow conversion and reducing debt.

Income Statement

Hims & Hers Health has shown impressive revenue growth with a TTM increase of 12.84%, indicating strong market demand. The company maintains a healthy gross profit margin of 76.20% and a net profit margin of 9.62%, reflecting efficient cost management and profitability. The EBIT and EBITDA margins have improved significantly, showcasing operational efficiency. However, the slight decline in gross profit margin from the previous year suggests potential cost pressures.

Balance Sheet

The balance sheet reveals a high debt-to-equity ratio of 1.86, indicating significant leverage which could pose financial risk. However, the company has a strong return on equity of 38.17%, demonstrating effective use of equity to generate profits. The equity ratio stands at 29.96%, suggesting a balanced capital structure but with room for improvement in reducing debt levels.

Cash Flow

The cash flow statement shows a decline in free cash flow growth by 46.10%, which is a concern for liquidity. The operating cash flow to net income ratio is close to 1, indicating that the company is generating sufficient cash from operations to cover its net income. However, the free cash flow to net income ratio of 48.72% suggests that a significant portion of earnings is not being converted into free cash flow, highlighting potential cash management issues.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.01B	1.48B	872.00M	526.92M	271.88M	148.76M
Gross Profit	1.53B	1.17B	714.95M	408.72M	204.49M	109.45M
EBITDA	154.78M	78.99M	-19.94M	-61.22M	-110.97M	-14.09M
Net Income	193.60M	126.04M	-23.55M	-65.68M	-107.66M	-18.11M
Balance Sheet
Total Assets	1.88B	707.54M	441.19M	366.34M	420.58M	118.70M
Cash, Cash Equivalents and Short-Term Investments	1.14B	300.25M	220.98M	179.63M	247.27M	100.21M
Total Debt	1.04B	11.35M	9.95M	5.31M	5.48M	0.00
Total Liabilities	1.31B	230.82M	97.16M	54.60M	85.97M	265.57M
Stockholders Equity	562.70M	476.72M	344.03M	311.74M	334.62M	-146.87M
Cash Flow
Free Cash Flow	119.51M	198.33M	46.99M	-33.78M	-39.42M	-6.71M
Operating Cash Flow	261.63M	251.08M	73.48M	-26.53M	-34.41M	-2.48M
Investing Cash Flow	-81.50M	-19.05M	-12.11M	34.70M	-156.27M	-39.70M
Financing Cash Flow	813.68M	-107.84M	-11.47M	-33.13M	235.04M	47.74M

Hims & Hers Health Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 57.82
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HIMS, the sentiment is Positive. The current price of 57.82 is above the 20-day moving average (MA) of 48.38, above the 50-day MA of 50.82, and above the 200-day MA of 42.67, indicating a bullish trend. The MACD of 1.65 indicates Negative momentum. The RSI at 63.86 is Neutral, neither overbought nor oversold. The STOCH value of 73.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HIMS.

Hims & Hers Health Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NUS	74 Outperform	598.43M	6.03	12.80%	1.99%	-11.79%	0.00%
HIMS	69 Neutral	$13.07B	72.37	41.88%	―	88.69%	947.74%
IPAR	65 Neutral	3.26B	20.29	27.41%	3.11%	7.04%	13.52%
EPC	58 Neutral	944.15M	15.01	4.13%	2.95%	-2.92%	-43.06%
SPB	57 Neutral	1.27B	19.66	3.85%	3.57%	-2.78%	-17.38%
COTY	47 Neutral	3.59B	-9.40	-9.98%	―	-3.68%	-631.67%
Sector *	62 Neutral	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%

Hims & Hers Health Corporate Events

Hims & Hers Health Expands with New Ohio Facility

On September 1, 2025, Hims, Inc., a subsidiary of Hims & Hers Health, Inc., signed a lease agreement for a 352,012 square foot facility in New Albany, Ohio, intended for office, research, development, laboratory, manufacturing, and pharmaceutical dispensing purposes. The 15-year lease, with options for extension, includes an annual base rent starting at $5,984,204, subject to annual increases and initial abatements. This move signifies a strategic expansion for Hims & Hers Health, potentially enhancing its operational capacity and market presence.

Hims & Hers Health Reports Strong Q2 2025 Financial Growth

Hims & Hers Health, Inc. reported significant financial growth in the second quarter of 2025, with a 73% increase in revenue year-over-year, reaching $544.8 million. The company also saw a 31% increase in subscribers, totaling over 2.4 million, and a net income of $42.5 million. The company is focusing on expanding its capabilities, including enhancing personalization in pharmacies, expanding lab testing, and growing its international presence, which is expected to further strengthen its market position.

Hims & Hers Health Annual Stockholders Meeting Results

On June 12, 2025, Hims & Hers Health, Inc. conducted its Annual Meeting of Stockholders where three proposals were voted on. The election of eight directors, the ratification of KPMG LLP as the independent registered public accounting firm, and the advisory approval of executive compensation were all passed, reflecting shareholder support for the company’s governance and financial strategies.